Immunodynamics of explanted human tumors for immuno-oncology

Agathe Dubuisson; Jean Eudes Fahrner; Anne Gaëlle Goubet; Safae Terrisse; Nicolas Voisin; Charles Bayard; Sebastien Lofek; Damien Drubay; Delphine Bredel; Séverine Mouraud; Sandrine Susini; Alexandria Cogdill; Lucas Rebuffet; Elise Ballot; Nicolas Jacquelot; Vincent Thomas de Montpreville; Odile Casiraghi; Camélia Radulescu; Sophie Ferlicot; David J. Figueroa; Sapna Yadavilli; Jeremy D. Waight; Marc Ballas; Axel Hoos; Thomas Condamine; Bastien Parier; Christophe Gaudillat; Bertrand Routy; François Ghiringhelli; Lisa Derosa; Ingrid Breuskin; Mathieu Rouanne; Fabrice André; Cédric Lebacle; Hervé Baumert; Marie Wislez; Elie Fadel; Isabelle Cremer; Laurence Albiges; Birgit Geoerger; Jean Yves Scoazec; Yohann Loriot; Guido Kroemer; Aurélien Marabelle; Mélodie Bonvalet; Laurence Zitvogel

doi:10.15252/emmm.202012850

Immunodynamics of explanted human tumors for immuno-oncology

Agathe Dubuisson, Jean Eudes Fahrner, Anne Gaëlle Goubet, Safae Terrisse, Nicolas Voisin, Charles Bayard, Sebastien Lofek, Damien Drubay, Delphine Bredel, Séverine Mouraud, Sandrine Susini, Alexandria Cogdill, Lucas Rebuffet, Elise Ballot, Nicolas Jacquelot, Vincent Thomas de Montpreville, Odile Casiraghi, Camélia Radulescu, Sophie Ferlicot, David J. FigueroaSapna Yadavilli, Jeremy D. Waight, Marc Ballas, Axel Hoos, Thomas Condamine, Bastien Parier, Christophe Gaudillat, Bertrand Routy, François Ghiringhelli, Lisa Derosa, Ingrid Breuskin, Mathieu Rouanne, Fabrice André, Cédric Lebacle, Hervé Baumert, Marie Wislez, Elie Fadel, Isabelle Cremer, Laurence Albiges, Birgit Geoerger, Jean Yves Scoazec, Yohann Loriot, Guido Kroemer, Aurélien Marabelle, Mélodie Bonvalet, Laurence Zitvogel

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

9 Citations (Scopus)

Résumé

Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno-assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti-PD-1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.

langue originale	Anglais
Numéro d'article	e12850
journal	EMBO Molecular Medicine
Volume	13
Numéro de publication	1
Les DOIs	https://doi.org/10.15252/emmm.202012850
état	Publié - 11 janv. 2021

Accès au document

10.15252/emmm.202012850

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Dubuisson, A., Fahrner, J. E., Goubet, A. G., Terrisse, S., Voisin, N., Bayard, C., Lofek, S., Drubay, D., Bredel, D., Mouraud, S., Susini, S., Cogdill, A., Rebuffet, L., Ballot, E., Jacquelot, N., Thomas de Montpreville, V., Casiraghi, O., Radulescu, C., Ferlicot, S., ... Zitvogel, L. (2021). Immunodynamics of explanted human tumors for immuno-oncology. EMBO Molecular Medicine, 13(1), Article e12850. https://doi.org/10.15252/emmm.202012850

@article{caaa78ea6f24421aa2c7e6419b5ec6d1,

title = "Immunodynamics of explanted human tumors for immuno-oncology",

abstract = "Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno-assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This {"}in sitro{"} (in situ/in vitro) assay has the potential to predict unresponsiveness to anti-PD-1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.",

keywords = "cancer, immune checkpoint inhibitors, immunomonitoring, precision oncology, “in sitro” assay",

author = "Agathe Dubuisson and Fahrner, {Jean Eudes} and Goubet, {Anne Ga{\"e}lle} and Safae Terrisse and Nicolas Voisin and Charles Bayard and Sebastien Lofek and Damien Drubay and Delphine Bredel and S{\'e}verine Mouraud and Sandrine Susini and Alexandria Cogdill and Lucas Rebuffet and Elise Ballot and Nicolas Jacquelot and {Thomas de Montpreville}, Vincent and Odile Casiraghi and Cam{\'e}lia Radulescu and Sophie Ferlicot and Figueroa, {David J.} and Sapna Yadavilli and Waight, {Jeremy D.} and Marc Ballas and Axel Hoos and Thomas Condamine and Bastien Parier and Christophe Gaudillat and Bertrand Routy and Fran{\c c}ois Ghiringhelli and Lisa Derosa and Ingrid Breuskin and Mathieu Rouanne and Fabrice Andr{\'e} and C{\'e}dric Lebacle and Herv{\'e} Baumert and Marie Wislez and Elie Fadel and Isabelle Cremer and Laurence Albiges and Birgit Geoerger and Scoazec, {Jean Yves} and Yohann Loriot and Guido Kroemer and Aur{\'e}lien Marabelle and M{\'e}lodie Bonvalet and Laurence Zitvogel",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Published under the terms of the CC BY 4.0 license",

year = "2021",

month = jan,

day = "11",

doi = "10.15252/emmm.202012850",

language = "English",

volume = "13",

journal = "EMBO Molecular Medicine",

issn = "1757-4676",

number = "1",

}

Dubuisson, A, Fahrner, JE, Goubet, AG, Terrisse, S, Voisin, N, Bayard, C, Lofek, S, Drubay, D, Bredel, D, Mouraud, S, Susini, S, Cogdill, A, Rebuffet, L, Ballot, E, Jacquelot, N, Thomas de Montpreville, V, Casiraghi, O, Radulescu, C, Ferlicot, S, Figueroa, DJ, Yadavilli, S, Waight, JD, Ballas, M, Hoos, A, Condamine, T, Parier, B, Gaudillat, C, Routy, B, Ghiringhelli, F, Derosa, L, Breuskin, I, Rouanne, M, André, F, Lebacle, C, Baumert, H, Wislez, M, Fadel, E, Cremer, I, Albiges, L, Geoerger, B, Scoazec, JY, Loriot, Y, Kroemer, G, Marabelle, A, Bonvalet, M & Zitvogel, L 2021, 'Immunodynamics of explanted human tumors for immuno-oncology', EMBO Molecular Medicine, VOL. 13, Numéro 1, e12850. https://doi.org/10.15252/emmm.202012850

TY - JOUR

T1 - Immunodynamics of explanted human tumors for immuno-oncology

AU - Dubuisson, Agathe

AU - Fahrner, Jean Eudes

AU - Goubet, Anne Gaëlle

AU - Terrisse, Safae

AU - Voisin, Nicolas

AU - Bayard, Charles

AU - Lofek, Sebastien

AU - Drubay, Damien

AU - Bredel, Delphine

AU - Mouraud, Séverine

AU - Susini, Sandrine

AU - Cogdill, Alexandria

AU - Rebuffet, Lucas

AU - Ballot, Elise

AU - Jacquelot, Nicolas

AU - Thomas de Montpreville, Vincent

AU - Casiraghi, Odile

AU - Radulescu, Camélia

AU - Ferlicot, Sophie

AU - Figueroa, David J.

AU - Yadavilli, Sapna

AU - Waight, Jeremy D.

AU - Ballas, Marc

AU - Hoos, Axel

AU - Condamine, Thomas

AU - Parier, Bastien

AU - Gaudillat, Christophe

AU - Routy, Bertrand

AU - Ghiringhelli, François

AU - Derosa, Lisa

AU - Breuskin, Ingrid

AU - Rouanne, Mathieu

AU - André, Fabrice

AU - Lebacle, Cédric

AU - Baumert, Hervé

AU - Wislez, Marie

AU - Fadel, Elie

AU - Cremer, Isabelle

AU - Albiges, Laurence

AU - Geoerger, Birgit

AU - Scoazec, Jean Yves

AU - Loriot, Yohann

AU - Kroemer, Guido

AU - Marabelle, Aurélien

AU - Bonvalet, Mélodie

AU - Zitvogel, Laurence

PY - 2021/1/11

Y1 - 2021/1/11

N2 - Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno-assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti-PD-1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.

AB - Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno-assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti-PD-1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.

KW - cancer

KW - immune checkpoint inhibitors

KW - immunomonitoring

KW - precision oncology

KW - “in sitro” assay

UR - http://www.scopus.com/inward/record.url?scp=85098103998&partnerID=8YFLogxK

U2 - 10.15252/emmm.202012850

DO - 10.15252/emmm.202012850

M3 - Article

C2 - 33372722

AN - SCOPUS:85098103998

SN - 1757-4676

VL - 13

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

IS - 1

M1 - e12850

ER -